Delcath SystemsDCTH 70 EV-to-FCF is 18.67 as of Jun. 29, 2026. GuruFocus rates DCTH with a GF Score™ of 70/100 and a GF Value™ of $36.72 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 418 Medical Devices & Instruments companies, Delcath Systems ranks better than 60.05% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Delcath Systems's Enterprise Value is $358.32 Mil.
Delcath Systems's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $19.19 Mil. Therefore, Delcath Systems's EV-to-FCF for today is 18.67.
The historical rank and industry rank for Delcath Systems's EV-to-FCF or its related term are showing as below:
DCTH'
s EV-to-FCF Range Over the Past 10 Years
Min: -934.95 Med: -1.72 Max: 111.44
Current: 18.67
During the past 13 years, the highest EV-to-FCF of Delcath Systems was 111.44. The lowest was -934.95. And the median was -1.72.
DCTH's EV-to-FCF is ranked better than 60.05% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.765
vs DCTH: 18.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Delcath Systems's PE Ratio (TTM) for today is calculated as:
Delcath Systems's share price for today is $12.94.
Delcath Systems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Delcath Systems EV-to-FCF Related Terms
Delcath Systems EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Delcath Systems's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Delcath Systems's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delcath Systems EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Delcath Systems's EV-to-FCF falls into.
Delcath Systems's current Enterprise Value is $358.32 Mil.
Delcath Systems's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Delcath Systems (DCTH) has a EV-to-FCF of 18.67 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Delcath Systems and its competitors. According to the industry distribution chart, Delcath Systems ranks #167 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 40%.
Is Delcath Systems' EV-to-FCF too high?
Delcath Systems' current EV-to-FCF is 18.67. The Medical Devices & Instruments industry median EV-to-FCF is 22.77. Delcath Systems' value of 18.67 is 18% below this industry median. Based on the distribution chart, Delcath Systems ranks #167 out of 418 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Delcath Systems has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' EV-to-FCF compare to VMD and VREX?
According to the Medical Devices & Instruments industry distribution chart, Delcath Systems ranks #167 out of 418 companies for EV-to-FCF. This puts Delcath Systems in the upper half of its industry. The industry median EV-to-FCF is 22.77. Delcath Systems' value of 18.67 is 18% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.77, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delcath Systems's current EV-to-FCF of 18.67 is 18% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Delcath Systems and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delcath Systems's current EV-to-FCF is 18.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.72, compared to a current price of $12.94 — trading 64.8% below its estimated fair value. The current EV-to-FCF is 18.67 and 18% below the Medical Devices & Instruments industry median of 22.77. Delcath Systems' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Delcath Systems (DCTH), the current EV-to-FCF is 18.67 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delcath Systems (DCTH) Overvalued in 2026?
Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued.
The current stock price of $12.94 is trading 64.8% below its estimated GF Value™ of $36.72.
GuruFocus considers Delcath Systems to be Significantly Undervalued.
Key valuation signals for DCTH:
EV-to-FCF: 18.67
GF Value™: $36.72 vs. price of $12.94 (64.8% below fair value)
Industry Position: 18% below the Medical Devices & Instruments median (#167 of 418)
No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score
Get the complete analysis for DCTH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCTH has been successfully added to your 
